GINX - AI Analysis

Compare

Top Page

SGI Enhanced Global Income ETF (GINX)

Rating:60Neutral

Price Target:

$31.00

The SGI Enhanced Global Income ETF (GINX) has a balanced rating, reflecting a mix of strong and moderate-performing holdings. Taiwan Semiconductor Manufacturing Company (TSM) stands out as a key contributor, driven by its robust financial performance and demand for advanced technologies, though its high valuation suggests growth expectations are already priced in. On the other hand, holdings like Colgate-Palmolive (CL) and AbbVie (ABBV) face challenges such as high leverage and valuation concerns, which may have slightly weighed on the overall rating. The ETF’s diversified holdings help mitigate risks, but investors should note potential vulnerabilities in valuation and leverage across some assets.

Positive Factors

Strong Year-to-Date Performance

The ETF has delivered solid gains so far this year, indicating strong overall momentum.

Sector Diversification

The fund is spread across 11 sectors, reducing the risk of heavy losses from a downturn in any single industry.

Global Exposure

While primarily focused on the U.S., the ETF includes holdings from Canada and Japan, adding some international diversification.

Negative Factors

High Expense Ratio

The ETF charges a relatively high fee compared to similar funds, which can eat into investor returns over time.

Underperforming Holdings

Some top holdings, like Merck and Colgate-Palmolive, have lagged this year, potentially dragging down overall performance.

U.S.-Heavy Allocation

Nearly 80% of the fund is invested in U.S. companies, limiting exposure to global markets and diversification benefits.

GINX vs. SPDR S&P 500 ETF (SPY)

AUM81.97M

RegionGlobal

Expense Ratio0.99%

Beta0.72

IssuerSummit Global Investments

Inception DateFeb 29, 2024

Dividend Yield6.08%

Asset ClassEquity

Index TrackedNo Underlying Index

Share Statistics

EPS (TTM)N/A

Shares OutstandingN/A

10 Day Avg. Volume13,458

30 Day Avg. Volume10,885

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

GINX Summary

The SGI Enhanced Global Income ETF (Ticker: GINX) is an investment fund designed to provide income and diversification by holding a mix of companies from various sectors and regions. It focuses on the total market, with a strong emphasis on income-generating assets. Some well-known companies in its portfolio include Merck & Company and Colgate-Palmolive. This ETF is ideal for investors looking to enhance their portfolio's income potential while gaining exposure to a wide range of industries and countries. However, new investors should be aware that the fund's performance can fluctuate with global market conditions, which may impact returns.

How much will it cost me?The SGI Enhanced Global Income ETF (GINX) has an expense ratio of 0.99%, which means you’ll pay $9.90 per year for every $1,000 invested. This is higher than average because it is actively managed, aiming to maximize global income opportunities through a dynamic and diversified strategy.

What would affect this ETF?The SGI Enhanced Global Income ETF (GINX) could benefit from global economic growth, particularly in sectors like financials and technology, which are heavily weighted in its portfolio. However, rising interest rates or regulatory changes in key industries like healthcare and energy could negatively impact its income-generating capabilities. Additionally, geopolitical tensions or economic slowdowns in regions where GINX has significant exposure may pose risks to its performance.

GINX Top 10 Holdings

The SGI Enhanced Global Income ETF (GINX) is leaning heavily on financials, with Banco Bilbao (BBVA) showing strong momentum and helping drive performance. Health care names like Merck and AbbVie are steady contributors, though Merck’s recent struggles with revenue growth have slightly dampened its impact. On the flip side, consumer staples giant Colgate-Palmolive is lagging, holding back gains with bearish signals. Technology exposure, including TSMC, adds a spark with rising demand for advanced tech. Overall, the fund’s global mix and sector diversity provide a balanced approach, though financials dominate the narrative.

Name	Company Name	Weight %	Market Value	Market Cap	Yearly Gain	Overall Rating
	―	3.37%	$2.76M	―	―	―
	―	3.13%	$2.56M	―	―	―
BBVA	Banco Bilbao	2.98%	$2.44M	$113.28B	103.15%	64 Neutral
	―	2.83%	$2.32M	―	―	―
MRK	Merck & Company	2.83%	$2.32M	$218.53B	-15.57%	76 Outperform
CL	Colgate-Palmolive	2.49%	$2.04M	$63.04B	-18.71%	68 Neutral
TSM	TSMC	2.32%	$1.90M	$1.23T	53.20%	81 Outperform
DTE	DTE Energy	2.17%	$1.78M	$29.44B	11.84%	70 Neutral
ABBV	AbbVie	2.14%	$1.75M	$402.76B	20.22%	64 Neutral
QCOM	Qualcomm	2.14%	$1.75M	$182.29B	8.98%	78 Outperform

GINX Technical Analysis

Technical Analysis Sentiment

Positive

Last Price―

Price Trends

50DMA

28.88

Positive

100DMA

28.11

Positive

200DMA

26.95

Positive

Market Momentum

MACD

0.21

Negative

RSI

65.40

Neutral

STOCH

93.43

Negative

Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For GINX, the sentiment is Positive. The current price of undefined is equal to the 20-day moving average (MA) of 29.43, equal to the 50-day MA of 28.88, and equal to the 200-day MA of 26.95, indicating a bullish trend. The MACD of 0.21 indicates Negative momentum. The RSI at 65.40 is Neutral, neither overbought nor oversold. The STOCH value of 93.43 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for GINX.

GINX Peer Comparison

Comparison Results

Name	Price	Price Target	AUM	Expense Ratio	Overall Rating
GINX	―	―	$81.97M	0.99%	60 Neutral
TOLL	―	―	$72.75M	0.55%	74 Outperform
ICAP	―	―	$70.50M	3.19%	73 Outperform
GOP	―	―	$60.95M	0.75%	69 Neutral
CAMX	―	―	$60.32M	0.59%	68 Neutral
SAGP	―	―	$59.71M	0.65%	65 Neutral

Performance Comparison

GINX

SGI Enhanced Global Income ETF

29.82

4.82

19.28%

TOLL

Tema Monopolies and Oligopolies ETF

―

ICAP

InfraCap Equity Income Fund ETF

―

GOP

Unusual Whales Subversive Republican Trading ETF

―

CAMX

Cambiar Aggressive Value ETF

―

SAGP

Strategas Global Policy Opportunities ETF

―

Glossary

BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―

Table of Contents